Vincerx Pharma is a clinical-stage biopharmaceutical company focused on utilizing its development and oncology capabilities to advance therapies intended to address unmet medical needs for the treatment of cancer. The small molecule drug program includes VIP152, which is a selective, clinical-stage positive transcription elongation factor beta/cyclin-dependent kinase 9 inhibitor. Co.'s antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate for solid tumors. We show 10 historical shares outstanding datapoints in our coverage of VINC's shares outstanding history.
Understanding the changing numbers of VINC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VINC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VINC by allowing them to research VINC shares outstanding history
as well as any other stock in our coverage universe. |
Free VINC Email Alerts:
Video: Shares Outstanding Importance
